Page 60 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GESMD
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination With Veneto-
clax and/or Azacitidine in Subjects With Acute Myeloid Leukemia (AML) or Myelodys-
plastic Syndrome (MDS). Fase I. Hospital Universitario Fundación Jiménez Díaz, Hospital
Clínic de Barcelona. Finalizado.
• A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmaco-
kinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Myelopro-
liferative Neoplasm Subjects. Fase I. ICO L’Hospitalet-Hospital Duran i Reynals. Activo,
sin reclutamiento.
• ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab
in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve
Patients With Higher Risk Myelodysplastic Syndrome. Fase III. Hospital Universitario de
Salamanca, Hospital Clínico Universitario de Valencia, Clínica Universidad de Navarra
(Madrid), Hospital Universitario Fundación Jiménez Díaz, ICO L’Hospitalet-Hospital Duran
i Reynals, Hospital Universitario Vall d’Hebron, Hospital Regional Universitario de Málaga.
Finalizado.
• M15-954: A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Ef-
ficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With
Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS). Fase III. Hospital Universitario
de Salamanca, Hospital General Universitario Gregorio Marañón, Hospital Universitario
12 de Octubre, Hospital Universitario Vall d’Hebron, Hospital Universitari i Politècnic La
Fe, ICO Badalona-Hospital Germans Trias i Pujol. Finalizado.
• A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Li-
gase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leuke-
mia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes. Fase I. Clínica
Universidad de Navarra, ICO Badalona-Hospital Germans Trias i Pujol, Hospital Universi-
tario de Salamanca. Activo sin reclutamiento.
• A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selec-
tive Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients
With Newly Diagnosed and Relapsed/Refractory Cancer Indications. Fase I-II. Hospital
Clínic de Barcelona, Clínica Universidad de Navarra, Hospital Universitario Central de
Asturias. Finalizado prematuramente.
60